Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

459
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
459
Angina IV: Management01:26

Angina IV: Management

315
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
315
Lipid Absorption01:24

Lipid Absorption

2.8K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.8K
Lipid Digestion01:06

Lipid Digestion

100.1K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
100.1K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.2K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy.

Journal of clinical lipidology·2019
Same author

JCL roundtable: Managing lipid disorders in patients with HIV.

Journal of clinical lipidology·2017
Same author

Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin.

Journal of lipid research·2017
Same author

JCL roundtable: Risk evaluation and mitigation strategy.

Journal of clinical lipidology·2016
Same author

Predictors of Calf Arterial Compliance in Male Veterans With Psychiatric Diagnoses.

The primary care companion for CNS disorders·2016
Same author

From the Editor: New and good are not the same!

Journal of clinical lipidology·2016
Same journal

CV risk: if you aren't testing ACR, you aren't seeing the full picture.

Postgraduate medicine·2026
Same journal

Anti-TNF-induced vasculitis: analysis of data from the French national pharmacovigilance database.

Postgraduate medicine·2026
Same journal

Relationship of serum nesfatin-1 levels with body mass index and c-reactive protein in patients presenting to the emergency department with epileptic seizures.

Postgraduate medicine·2026
Same journal

Clinical pharmacokinetics of colistimethate sodium and formed colistin in patients with renal impairment or on dialysis modalities: a systematic review and implications for precision dosing.

Postgraduate medicine·2026
Same journal

The role of type D personality in pregnancy symptom severity, functional limitations, and maternal ambivalence.

Postgraduate medicine·2026
Same journal

Operational and demographic predictors of leaving without being seen in a high-volume tertiary emergency department: a five-year case-control study.

Postgraduate medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Niacin for lipid disorders.

W Virgil Brown

    Postgraduate Medicine
    |December 12, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Niacin, a long-established lipid-lowering agent, effectively reduces LDL cholesterol and triglycerides while increasing HDL cholesterol. Despite its benefits, adverse reactions limit its optimal use in treating dyslipidemia.

    More Related Videos

    Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
    04:14

    Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

    Published on: April 16, 2019

    12.7K
    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
    07:29

    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

    Published on: October 12, 2017

    9.8K

    Related Experiment Videos

    Last Updated: Feb 17, 2026

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    15.1K
    Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
    04:14

    Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

    Published on: April 16, 2019

    12.7K
    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
    07:29

    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

    Published on: October 12, 2017

    9.8K

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology

    Background:

    • Niacin (nicotinic acid) is the oldest available lipid-lowering agent.
    • It demonstrates efficacy in managing cholesterol and triglyceride levels.
    • Adverse reactions can limit its clinical application.

    Purpose of the Study:

    • To examine the current role of niacin in dyslipidemia treatment.
    • To discuss the balance between niacin's benefits and drawbacks.

    Main Methods:

    • Review of existing literature on niacin's efficacy and safety.
    • Clinical practice analysis regarding niacin's use in dyslipidemia.

    Main Results:

    • Niacin effectively lowers LDL cholesterol and triglycerides.
    • Niacin significantly raises HDL cholesterol levels.
    • High frequency of adverse reactions hinders optimal physician utilization.

    Conclusions:

    • Niacin remains a valuable tool for dyslipidemia management.
    • Strategies to mitigate adverse effects are crucial for maximizing niacin's therapeutic potential.
    • Further research may clarify optimal niacin dosing and patient selection.